Agile Therapeutics, Inc. (AGRX) Earns Buy Rating from Janney Montgomery Scott
Agile Therapeutics, Inc. (NASDAQ:AGRX)‘s stock had its “buy” rating reiterated by stock analysts at Janney Montgomery Scott in a note issued to investors on Thursday. They presently have a $13.00 price objective on the specialty pharmaceutical company’s stock. Janney Montgomery Scott’s price target points to a potential upside of 283.48% from the stock’s current price.
A number of other brokerages also recently commented on AGRX. Noble Financial restated a “buy” rating on shares of Agile Therapeutics in a research report on Sunday, July 30th. HC Wainwright began coverage on shares of Agile Therapeutics in a research report on Wednesday, July 19th. They issued a “buy” rating and a $10.00 price objective for the company. Royal Bank Of Canada set a $8.00 price objective on shares of Agile Therapeutics and gave the company a “buy” rating in a research report on Sunday, July 16th. Finally, ValuEngine upgraded shares of Agile Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 8th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. Agile Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $8.75.
Shares of Agile Therapeutics (NASDAQ AGRX) traded up 1.50% during trading on Thursday, hitting $3.39. The company had a trading volume of 344,502 shares. The stock’s 50-day moving average is $3.80 and its 200 day moving average is $3.40. Agile Therapeutics has a 52-week low of $1.82 and a 52-week high of $7.95. The firm’s market capitalization is $97.65 million.
Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings data on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.02. During the same quarter last year, the company posted ($0.29) earnings per share. Equities research analysts predict that Agile Therapeutics will post ($1.03) earnings per share for the current fiscal year.
WARNING: “Agile Therapeutics, Inc. (AGRX) Earns Buy Rating from Janney Montgomery Scott” was posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/09/07/agile-therapeutics-inc-agrx-earns-buy-rating-from-janney-montgomery-scott.html.
In other Agile Therapeutics news, Chairman Alfred Altomari acquired 10,000 shares of the company’s stock in a transaction dated Friday, August 25th. The stock was acquired at an average cost of $3.34 per share, with a total value of $33,400.00. Following the purchase, the chairman now directly owns 161,587 shares in the company, valued at approximately $539,700.58. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 3.50% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in AGRX. Royce & Associates LP grew its stake in Agile Therapeutics by 206.1% in the 1st quarter. Royce & Associates LP now owns 987,582 shares of the specialty pharmaceutical company’s stock worth $3,165,000 after acquiring an additional 665,000 shares during the period. Janney Montgomery Scott LLC purchased a new stake in Agile Therapeutics in the 2nd quarter worth approximately $122,000. LMR Partners LLP purchased a new stake in Agile Therapeutics in the 2nd quarter worth approximately $211,000. Franklin Resources Inc. grew its stake in Agile Therapeutics by 39.2% in the 2nd quarter. Franklin Resources Inc. now owns 2,772,200 shares of the specialty pharmaceutical company’s stock worth $10,396,000 after acquiring an additional 780,578 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in Agile Therapeutics by 604.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 95,820 shares of the specialty pharmaceutical company’s stock worth $359,000 after acquiring an additional 82,213 shares during the period. 67.59% of the stock is owned by hedge funds and other institutional investors.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.